4tw9 - Revision history

OCA at 11:18, 9 May 2024

2024-05-09T11:18:39Z

←Older revision		Revision as of 11:18, 9 May 2024
Line 4:		Line 4:
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[4tw9]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4TW9 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4TW9 FirstGlance]. <br>		<table><tr><td colspan='2'>[[4tw9]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4TW9 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4TW9 FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=386:N-(2,2-DIFLUORO-5H-[1,3]DIOXOLO[4,5-F]BENZIMIDAZOL-6-YL)-2-{[2-(TRIFLUOROMETHOXY)BENZOYL]AMINO}-1,3-THIAZOLE-4-CARBOXAMIDE'>386</scene>, <scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=HSJ:OCTYL+BETA-L-TALOPYRANOSIDE'>HSJ</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 2.4Å</td></tr>
		+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=386:N-(2,2-DIFLUORO-5H-[1,3]DIOXOLO[4,5-F]BENZIMIDAZOL-6-YL)-2-{[2-(TRIFLUOROMETHOXY)BENZOYL]AMINO}-1,3-THIAZOLE-4-CARBOXAMIDE'>386</scene>, <scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=HSJ:OCTYL+BETA-L-TALOPYRANOSIDE'>HSJ</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4tw9 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4tw9 OCA], [https://pdbe.org/4tw9 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4tw9 RCSB], [https://www.ebi.ac.uk/pdbsum/4tw9 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4tw9 ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4tw9 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4tw9 OCA], [https://pdbe.org/4tw9 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4tw9 RCSB], [https://www.ebi.ac.uk/pdbsum/4tw9 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4tw9 ProSAT]</span></td></tr>
	</table>		</table>

OCA at 10:58, 15 March 2023

2023-03-15T10:58:46Z

←Older revision		Revision as of 10:58, 15 March 2023
Line 3:		Line 3:
	<StructureSection load='4tw9' size='340' side='right'caption='[[4tw9]], [[Resolution\|resolution]] 2.40Å' scene=''>		<StructureSection load='4tw9' size='340' side='right'caption='[[4tw9]], [[Resolution\|resolution]] 2.40Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[4tw9]] is a 2 chain structure with sequence from [~~http~~://en.wikipedia.org/wiki/~~Human Human~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4TW9 OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=4TW9 FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[4tw9]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4TW9 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4TW9 FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=386:N-(2,2-DIFLUORO-5H-[1,3]DIOXOLO[4,5-F]BENZIMIDAZOL-6-YL)-2-{[2-(TRIFLUOROMETHOXY)BENZOYL]AMINO}-1,3-THIAZOLE-4-CARBOXAMIDE'>386</scene>, <scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=HSJ:OCTYL+BETA-L-TALOPYRANOSIDE'>HSJ</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene>~~</td></tr>~~	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=386:N-(2,2-DIFLUORO-5H-[1,3]DIOXOLO[4,5-F]BENZIMIDAZOL-6-YL)-2-{[2-(TRIFLUOROMETHOXY)BENZOYL]AMINO}-1,3-THIAZOLE-4-CARBOXAMIDE'>386</scene>, <scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=HSJ:OCTYL+BETA-L-TALOPYRANOSIDE'>HSJ</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>
-	~~<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">CSNK1D, HCKID ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])~~</td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4tw9 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4tw9 OCA], [https://pdbe.org/4tw9 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4tw9 RCSB], [https://www.ebi.ac.uk/pdbsum/4tw9 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4tw9 ProSAT]</span></td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=4tw9 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4tw9 OCA], [~~http~~://pdbe.org/4tw9 PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=4tw9 RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/4tw9 PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=4tw9 ProSAT]</span></td></tr>	+
	</table>		</table>
	== Disease ==		== Disease ==
-	[~~[http~~://www.uniprot.org/uniprot/KC1D_HUMAN KC1D_HUMAN]] Familial advanced sleep-phase syndrome. The disease is caused by mutations affecting the gene represented in this entry.	+	[https://www.uniprot.org/uniprot/KC1D_HUMAN KC1D_HUMAN] Familial advanced sleep-phase syndrome. The disease is caused by mutations affecting the gene represented in this entry.
	== Function ==		== Function ==
-	[~~[http~~://www.uniprot.org/uniprot/KC1D_HUMAN KC1D_HUMAN]] Essential serine/threonine-protein kinase that regulates diverse cellular growth and survival processes including Wnt signaling, DNA repair and circadian rhythms. It can phosphorylate a large number of proteins. Casein kinases are operationally defined by their preferential utilization of acidic proteins such as caseins as substrates. Phosphorylates connexin-43/GJA1, MAP1A, SNAPIN, MAPT/TAU, TOP2A, DCK, HIF1A, EIF6, p53/TP53, DVL2, DVL3, ESR1, AIB1/NCOA3, DNMT1, PKD2, YAP1, PER1 and PER2. Central component of the circadian clock. May act as a negative regulator of circadian rhythmicity by phosphorylating PER1 and PER2, leading to retain PER1 in the cytoplasm. YAP1 phosphorylation promotes its SCF(beta-TRCP) E3 ubiquitin ligase-mediated ubiquitination and subsequent degradation. DNMT1 phosphorylation reduces its DNA-binding activity. Phosphorylation of ESR1 and AIB1/NCOA3 stimulates their activity and coactivation. Phosphorylation of DVL2 and DVL3 regulates WNT3A signaling pathway that controls neurite outgrowth. EIF6 phosphorylation promotes its nuclear export. Triggers down-regulation of dopamine receptors in the forebrain. Activates DCK in vitro by phosphorylation. TOP2A phosphorylation favors DNA cleavable complex formation. May regulate the formation of the mitotic spindle apparatus in extravillous trophoblast. Modulates connexin-43/GJA1 gap junction assembly by phosphorylation. Probably involved in lymphocyte physiology. Regulates fast synaptic transmission mediated by glutamate.<ref>PMID:10606744</ref> <ref>PMID:12270943</ref> <ref>PMID:14761950</ref> <ref>PMID:16027726</ref> <ref>PMID:17962809</ref> <ref>PMID:17562708</ref> <ref>PMID:19043076</ref> <ref>PMID:19339517</ref> <ref>PMID:20637175</ref> <ref>PMID:20041275</ref> <ref>PMID:20048001</ref> <ref>PMID:20699359</ref> <ref>PMID:20696890</ref> <ref>PMID:20407760</ref> <ref>PMID:21084295</ref> <ref>PMID:21422228</ref>	+	[https://www.uniprot.org/uniprot/KC1D_HUMAN KC1D_HUMAN] Essential serine/threonine-protein kinase that regulates diverse cellular growth and survival processes including Wnt signaling, DNA repair and circadian rhythms. It can phosphorylate a large number of proteins. Casein kinases are operationally defined by their preferential utilization of acidic proteins such as caseins as substrates. Phosphorylates connexin-43/GJA1, MAP1A, SNAPIN, MAPT/TAU, TOP2A, DCK, HIF1A, EIF6, p53/TP53, DVL2, DVL3, ESR1, AIB1/NCOA3, DNMT1, PKD2, YAP1, PER1 and PER2. Central component of the circadian clock. May act as a negative regulator of circadian rhythmicity by phosphorylating PER1 and PER2, leading to retain PER1 in the cytoplasm. YAP1 phosphorylation promotes its SCF(beta-TRCP) E3 ubiquitin ligase-mediated ubiquitination and subsequent degradation. DNMT1 phosphorylation reduces its DNA-binding activity. Phosphorylation of ESR1 and AIB1/NCOA3 stimulates their activity and coactivation. Phosphorylation of DVL2 and DVL3 regulates WNT3A signaling pathway that controls neurite outgrowth. EIF6 phosphorylation promotes its nuclear export. Triggers down-regulation of dopamine receptors in the forebrain. Activates DCK in vitro by phosphorylation. TOP2A phosphorylation favors DNA cleavable complex formation. May regulate the formation of the mitotic spindle apparatus in extravillous trophoblast. Modulates connexin-43/GJA1 gap junction assembly by phosphorylation. Probably involved in lymphocyte physiology. Regulates fast synaptic transmission mediated by glutamate.<ref>PMID:10606744</ref> <ref>PMID:12270943</ref> <ref>PMID:14761950</ref> <ref>PMID:16027726</ref> <ref>PMID:17962809</ref> <ref>PMID:17562708</ref> <ref>PMID:19043076</ref> <ref>PMID:19339517</ref> <ref>PMID:20637175</ref> <ref>PMID:20041275</ref> <ref>PMID:20048001</ref> <ref>PMID:20699359</ref> <ref>PMID:20696890</ref> <ref>PMID:20407760</ref> <ref>PMID:21084295</ref> <ref>PMID:21422228</ref>
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
	== Publication Abstract from PubMed ==		== Publication Abstract from PubMed ==
Line 28:		Line 27:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
-	[[Category: ~~Human~~]]	+	[[Category: Homo sapiens]]
	[[Category: Large Structures]]		[[Category: Large Structures]]
-	[[Category: Alscher, V]]	+	[[Category: Alscher V]]
-	[[Category: Berg, S]]	+	[[Category: Berg S]]
-	[[Category: Bischof, J]]	+	[[Category: Bischof J]]
-	[[Category: Garcia-Reyes, B]]	+	[[Category: Garcia-Reyes B]]
-	[[Category: Knippschild, U]]	+	[[Category: Knippschild U]]
-	[[Category: Kohlhof, H]]	+	[[Category: Kohlhof H]]
-	[[Category: Leban, J]]	+	[[Category: Leban J]]
-	[[Category: Othersen, O]]	+	[[Category: Othersen O]]
-	[[Category: Pospiech, I]]	+	[[Category: Pospiech I]]
-	[[Category: Richter, J]]	+	[[Category: Richter J]]
-	[[Category: Vitt, D]]	+	[[Category: Vitt D]]
-	[[Category: Zaja, M]]	+	[[Category: Zaja M]]
-	~~[[Category: Ck1delta]]~~	+
-	~~[[Category: Ck1epsilon]]~~	+
-	~~[[Category: Phosphorylation]]~~	+
-	~~[[Category: Small molecule inhibitor]]~~	+
-	~~[[Category: Transferase~~]]	+

OCA at 14:12, 10 May 2019

2019-05-10T14:12:23Z

←Older revision		Revision as of 14:12, 10 May 2019
Line 1:		Line 1:

	==Difluoro-dioxolo-benzoimidazol-benzamides as potent inhibitors of CK1delta and epsilon with nanomolar inhibitory activity on cancer cell proliferation==		==Difluoro-dioxolo-benzoimidazol-benzamides as potent inhibitors of CK1delta and epsilon with nanomolar inhibitory activity on cancer cell proliferation==
-	<StructureSection load='4tw9' size='340' side='right' caption='[[4tw9]], [[Resolution\|resolution]] 2.40Å' scene=''>	+	<StructureSection load='4tw9' size='340' side='right'caption='[[4tw9]], [[Resolution\|resolution]] 2.40Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[4tw9]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4TW9 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4TW9 FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[4tw9]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4TW9 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4TW9 FirstGlance]. <br>
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=386:N-(2,2-DIFLUORO-5H-[1,3]DIOXOLO[4,5-F]BENZIMIDAZOL-6-YL)-2-{[2-(TRIFLUOROMETHOXY)BENZOYL]AMINO}-1,3-THIAZOLE-4-CARBOXAMIDE'>386</scene>, <scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=HSJ:OCTYL+BETA-L-TALOPYRANOSIDE'>HSJ</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=386:N-(2,2-DIFLUORO-5H-[1,3]DIOXOLO[4,5-F]BENZIMIDAZOL-6-YL)-2-{[2-(TRIFLUOROMETHOXY)BENZOYL]AMINO}-1,3-THIAZOLE-4-CARBOXAMIDE'>386</scene>, <scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=HSJ:OCTYL+BETA-L-TALOPYRANOSIDE'>HSJ</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>
		+	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">CSNK1D, HCKID ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4tw9 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4tw9 OCA], [http://pdbe.org/4tw9 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4tw9 RCSB], [http://www.ebi.ac.uk/pdbsum/4tw9 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4tw9 ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4tw9 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4tw9 OCA], [http://pdbe.org/4tw9 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4tw9 RCSB], [http://www.ebi.ac.uk/pdbsum/4tw9 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4tw9 ProSAT]</span></td></tr>
	</table>		</table>
Line 22:		Line 23:

	==See Also==		==See Also==
-	*[[Casein kinase\|Casein kinase]]	+	*[[Casein kinase 3D structures\|Casein kinase 3D structures]]
	== References ==		== References ==
	<references/>		<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Human]]
		+	[[Category: Large Structures]]
	[[Category: Alscher, V]]		[[Category: Alscher, V]]
	[[Category: Berg, S]]		[[Category: Berg, S]]

OCA at 17:51, 11 August 2016

2016-08-11T17:51:45Z

←Older revision		Revision as of 17:51, 11 August 2016
Line 1:		Line 1:
		+
	==Difluoro-dioxolo-benzoimidazol-benzamides as potent inhibitors of CK1delta and epsilon with nanomolar inhibitory activity on cancer cell proliferation==		==Difluoro-dioxolo-benzoimidazol-benzamides as potent inhibitors of CK1delta and epsilon with nanomolar inhibitory activity on cancer cell proliferation==
	<StructureSection load='4tw9' size='340' side='right' caption='[[4tw9]], [[Resolution\|resolution]] 2.40Å' scene=''>		<StructureSection load='4tw9' size='340' side='right' caption='[[4tw9]], [[Resolution\|resolution]] 2.40Å' scene=''>
Line 4:		Line 5:
	<table><tr><td colspan='2'>[[4tw9]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4TW9 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4TW9 FirstGlance]. <br>		<table><tr><td colspan='2'>[[4tw9]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4TW9 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4TW9 FirstGlance]. <br>
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=386:N-(2,2-DIFLUORO-5H-[1,3]DIOXOLO[4,5-F]BENZIMIDAZOL-6-YL)-2-{[2-(TRIFLUOROMETHOXY)BENZOYL]AMINO}-1,3-THIAZOLE-4-CARBOXAMIDE'>386</scene>, <scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=HSJ:OCTYL+BETA-L-TALOPYRANOSIDE'>HSJ</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=386:N-(2,2-DIFLUORO-5H-[1,3]DIOXOLO[4,5-F]BENZIMIDAZOL-6-YL)-2-{[2-(TRIFLUOROMETHOXY)BENZOYL]AMINO}-1,3-THIAZOLE-4-CARBOXAMIDE'>386</scene>, <scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=HSJ:OCTYL+BETA-L-TALOPYRANOSIDE'>HSJ</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4tw9 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4tw9 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4tw9 RCSB], [http://www.ebi.ac.uk/pdbsum/4tw9 PDBsum]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4tw9 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4tw9 OCA], [http://pdbe.org/4tw9 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4tw9 RCSB], [http://www.ebi.ac.uk/pdbsum/4tw9 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4tw9 ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
Line 18:		Line 19:
	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>		From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
	</div>		</div>
		+	<div class="pdbe-citations 4tw9" style="background-color:#fffaf0;"></div>
		+
		+	==See Also==
		+	*[[Casein kinase\|Casein kinase]]
	== References ==		== References ==
	<references/>		<references/>

OCA at 08:08, 25 January 2015

2015-01-25T08:08:20Z

←Older revision		Revision as of 08:08, 25 January 2015
Line 22:		Line 22:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
-	[[Category: Alscher, V.]]	+	[[Category: Alscher, V]]
-	[[Category: Berg, S.]]	+	[[Category: Berg, S]]
-	[[Category: Bischof, J.]]	+	[[Category: Bischof, J]]
-	[[Category: Garcia-Reyes, B.]]	+	[[Category: Garcia-Reyes, B]]
-	[[Category: Knippschild, U.]]	+	[[Category: Knippschild, U]]
-	[[Category: Kohlhof, H.]]	+	[[Category: Kohlhof, H]]
-	[[Category: Leban, J.]]	+	[[Category: Leban, J]]
-	[[Category: Othersen, O.]]	+	[[Category: Othersen, O]]
-	[[Category: Pospiech, I.]]	+	[[Category: Pospiech, I]]
-	[[Category: Richter, J.]]	+	[[Category: Richter, J]]
-	[[Category: Vitt, D.]]	+	[[Category: Vitt, D]]
-	[[Category: Zaja, M.]]	+	[[Category: Zaja, M]]
	[[Category: Ck1delta]]		[[Category: Ck1delta]]
	[[Category: Ck1epsilon]]		[[Category: Ck1epsilon]]

OCA at 08:55, 22 October 2014

2014-10-22T08:55:44Z

←Older revision		Revision as of 08:55, 22 October 2014
Line 3:		Line 3:
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[4tw9]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4TW9 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4TW9 FirstGlance]. <br>		<table><tr><td colspan='2'>[[4tw9]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4TW9 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4TW9 FirstGlance]. <br>
-	</td></tr><tr><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=386:N-(2,2-DIFLUORO-5H-[1,3]DIOXOLO[4,5-F]BENZIMIDAZOL-6-YL)-2-{[2-(TRIFLUOROMETHOXY)BENZOYL]AMINO}-1,3-THIAZOLE-4-CARBOXAMIDE'>386</scene>, <scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=HSJ:OCTYL+BETA-L-TALOPYRANOSIDE'>HSJ</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene><br>	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=386:N-(2,2-DIFLUORO-5H-[1,3]DIOXOLO[4,5-F]BENZIMIDAZOL-6-YL)-2-{[2-(TRIFLUOROMETHOXY)BENZOYL]AMINO}-1,3-THIAZOLE-4-CARBOXAMIDE'>386</scene>, <scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=HSJ:OCTYL+BETA-L-TALOPYRANOSIDE'>HSJ</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>
-	<tr><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4tw9 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4tw9 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4tw9 RCSB], [http://www.ebi.ac.uk/pdbsum/4tw9 PDBsum]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4tw9 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4tw9 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4tw9 RCSB], [http://www.ebi.ac.uk/pdbsum/4tw9 PDBsum]</span></td></tr>
-	<table>	+	</table>
	== Disease ==		== Disease ==
	[[http://www.uniprot.org/uniprot/KC1D_HUMAN KC1D_HUMAN]] Familial advanced sleep-phase syndrome. The disease is caused by mutations affecting the gene represented in this entry.		[[http://www.uniprot.org/uniprot/KC1D_HUMAN KC1D_HUMAN]] Familial advanced sleep-phase syndrome. The disease is caused by mutations affecting the gene represented in this entry.

OCA at 05:51, 24 September 2014

2014-09-24T05:51:34Z

←Older revision		Revision as of 05:51, 24 September 2014
Line 10:		Line 10:
	== Function ==		== Function ==
	[[http://www.uniprot.org/uniprot/KC1D_HUMAN KC1D_HUMAN]] Essential serine/threonine-protein kinase that regulates diverse cellular growth and survival processes including Wnt signaling, DNA repair and circadian rhythms. It can phosphorylate a large number of proteins. Casein kinases are operationally defined by their preferential utilization of acidic proteins such as caseins as substrates. Phosphorylates connexin-43/GJA1, MAP1A, SNAPIN, MAPT/TAU, TOP2A, DCK, HIF1A, EIF6, p53/TP53, DVL2, DVL3, ESR1, AIB1/NCOA3, DNMT1, PKD2, YAP1, PER1 and PER2. Central component of the circadian clock. May act as a negative regulator of circadian rhythmicity by phosphorylating PER1 and PER2, leading to retain PER1 in the cytoplasm. YAP1 phosphorylation promotes its SCF(beta-TRCP) E3 ubiquitin ligase-mediated ubiquitination and subsequent degradation. DNMT1 phosphorylation reduces its DNA-binding activity. Phosphorylation of ESR1 and AIB1/NCOA3 stimulates their activity and coactivation. Phosphorylation of DVL2 and DVL3 regulates WNT3A signaling pathway that controls neurite outgrowth. EIF6 phosphorylation promotes its nuclear export. Triggers down-regulation of dopamine receptors in the forebrain. Activates DCK in vitro by phosphorylation. TOP2A phosphorylation favors DNA cleavable complex formation. May regulate the formation of the mitotic spindle apparatus in extravillous trophoblast. Modulates connexin-43/GJA1 gap junction assembly by phosphorylation. Probably involved in lymphocyte physiology. Regulates fast synaptic transmission mediated by glutamate.<ref>PMID:10606744</ref> <ref>PMID:12270943</ref> <ref>PMID:14761950</ref> <ref>PMID:16027726</ref> <ref>PMID:17962809</ref> <ref>PMID:17562708</ref> <ref>PMID:19043076</ref> <ref>PMID:19339517</ref> <ref>PMID:20637175</ref> <ref>PMID:20041275</ref> <ref>PMID:20048001</ref> <ref>PMID:20699359</ref> <ref>PMID:20696890</ref> <ref>PMID:20407760</ref> <ref>PMID:21084295</ref> <ref>PMID:21422228</ref>		[[http://www.uniprot.org/uniprot/KC1D_HUMAN KC1D_HUMAN]] Essential serine/threonine-protein kinase that regulates diverse cellular growth and survival processes including Wnt signaling, DNA repair and circadian rhythms. It can phosphorylate a large number of proteins. Casein kinases are operationally defined by their preferential utilization of acidic proteins such as caseins as substrates. Phosphorylates connexin-43/GJA1, MAP1A, SNAPIN, MAPT/TAU, TOP2A, DCK, HIF1A, EIF6, p53/TP53, DVL2, DVL3, ESR1, AIB1/NCOA3, DNMT1, PKD2, YAP1, PER1 and PER2. Central component of the circadian clock. May act as a negative regulator of circadian rhythmicity by phosphorylating PER1 and PER2, leading to retain PER1 in the cytoplasm. YAP1 phosphorylation promotes its SCF(beta-TRCP) E3 ubiquitin ligase-mediated ubiquitination and subsequent degradation. DNMT1 phosphorylation reduces its DNA-binding activity. Phosphorylation of ESR1 and AIB1/NCOA3 stimulates their activity and coactivation. Phosphorylation of DVL2 and DVL3 regulates WNT3A signaling pathway that controls neurite outgrowth. EIF6 phosphorylation promotes its nuclear export. Triggers down-regulation of dopamine receptors in the forebrain. Activates DCK in vitro by phosphorylation. TOP2A phosphorylation favors DNA cleavable complex formation. May regulate the formation of the mitotic spindle apparatus in extravillous trophoblast. Modulates connexin-43/GJA1 gap junction assembly by phosphorylation. Probably involved in lymphocyte physiology. Regulates fast synaptic transmission mediated by glutamate.<ref>PMID:10606744</ref> <ref>PMID:12270943</ref> <ref>PMID:14761950</ref> <ref>PMID:16027726</ref> <ref>PMID:17962809</ref> <ref>PMID:17562708</ref> <ref>PMID:19043076</ref> <ref>PMID:19339517</ref> <ref>PMID:20637175</ref> <ref>PMID:20041275</ref> <ref>PMID:20048001</ref> <ref>PMID:20699359</ref> <ref>PMID:20696890</ref> <ref>PMID:20407760</ref> <ref>PMID:21084295</ref> <ref>PMID:21422228</ref>
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	Deregulation of CK1 (casein kinase 1) activity can be involved in the development of several pathological disorders and diseases such as cancer. Therefore, research interest in identifying potent CK1-specific inhibitors is still increasing. A previously published potent and selective benzimidazole-derived CK1delta/epsilon-specific inhibitor compound with significant effects on several tumor cell lines was further modified to difluoro-dioxolo-benzoimidazole derivatives displaying remarkable inhibitory effects and increased intracellular availability. In the present study, we identified two heterocyclic molecules as new CK1-specific inhibitor compounds with favorable physicochemical properties and notable selectivity in a kinome-wide screen. Being compared to other CK1 isoforms, these compounds exhibited advanced isoform selectivity toward CK1delta. Moreover, newly designed compounds showed increased growth inhibitory activity in a panel of different tumor cell lines as determined by analyses of cell viability and cell cycle distribution. In summary, presented lead optimization resulted in new highly selective CK1delta-specific small molecule inhibitors with increased biological activity.
		+
		+	Difluoro-dioxolo-benzoimidazol-benzamides As Potent Inhibitors of CK1delta and epsilon with Nanomolar Inhibitory Activity on Cancer Cell Proliferation.,Richter J, Bischof J, Zaja M, Kohlhof H, Othersen O, Vitt D, Alscher V, Pospiech I, Garcia-Reyes B, Berg S, Leban J, Knippschild U J Med Chem. 2014 Sep 17. PMID:25191940<ref>PMID:25191940</ref>
		+
		+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
		+	</div>
	== References ==		== References ==
	<references/>		<references/>

OCA at 07:55, 30 July 2014

2014-07-30T07:55:29Z

←Older revision		Revision as of 07:55, 30 July 2014
Line 1:		Line 1:
-	'''~~Unreleased structure~~'''	+	==Difluoro-dioxolo-benzoimidazol-benzamides as potent inhibitors of CK1delta and epsilon with nanomolar inhibitory activity on cancer cell proliferation==
-		+	<StructureSection load='4tw9' size='340' side='right' caption='[[4tw9]], [[Resolution\|resolution]] 2.40Å' scene=''>
-	~~The entry~~ 4tw9 is ~~ON HOLD~~	+	== Structural highlights ==
-		+	<table><tr><td colspan='2'>[[4tw9]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4TW9 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4TW9 FirstGlance]. <br>
-	~~Authors~~: ~~Richter~~, J., ~~Bischof~~, J., ~~Zaja~~, M., ~~Kohlhof~~, H., ~~Othersen~~, O., ~~Vitt~~, D., Alscher, V., ~~Pospiech, I~~., Garcia-Reyes, B., ~~Berg, S~~., Leban, J., ~~Knippschild~~, U.	+	</td></tr><tr><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=386:N-(2,2-DIFLUORO-5H-[1,3]DIOXOLO[4,5-F]BENZIMIDAZOL-6-YL)-2-{[2-(TRIFLUOROMETHOXY)BENZOYL]AMINO}-1,3-THIAZOLE-4-CARBOXAMIDE'>386</scene>, <scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=HSJ:OCTYL+BETA-L-TALOPYRANOSIDE'>HSJ</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene><br>
-		+	<tr><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4tw9 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4tw9 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4tw9 RCSB], [http://www.ebi.ac.uk/pdbsum/4tw9 PDBsum]</span></td></tr>
-	~~Description~~: ~~Difluoro-dioxolo-benzoimidazol-benzamides as potent inhibitors of CK1delta and epsilon with nanomolar inhibitory activity on cancer cell proliferation~~	+	<table>
		+	== Disease ==
		+	[[http://www.uniprot.org/uniprot/KC1D_HUMAN KC1D_HUMAN]] Familial advanced sleep-phase syndrome. The disease is caused by mutations affecting the gene represented in this entry.
		+	== Function ==
		+	[[http://www.uniprot.org/uniprot/KC1D_HUMAN KC1D_HUMAN]] Essential serine/threonine-protein kinase that regulates diverse cellular growth and survival processes including Wnt signaling, DNA repair and circadian rhythms. It can phosphorylate a large number of proteins. Casein kinases are operationally defined by their preferential utilization of acidic proteins such as caseins as substrates. Phosphorylates connexin-43/GJA1, MAP1A, SNAPIN, MAPT/TAU, TOP2A, DCK, HIF1A, EIF6, p53/TP53, DVL2, DVL3, ESR1, AIB1/NCOA3, DNMT1, PKD2, YAP1, PER1 and PER2. Central component of the circadian clock. May act as a negative regulator of circadian rhythmicity by phosphorylating PER1 and PER2, leading to retain PER1 in the cytoplasm. YAP1 phosphorylation promotes its SCF(beta-TRCP) E3 ubiquitin ligase-mediated ubiquitination and subsequent degradation. DNMT1 phosphorylation reduces its DNA-binding activity. Phosphorylation of ESR1 and AIB1/NCOA3 stimulates their activity and coactivation. Phosphorylation of DVL2 and DVL3 regulates WNT3A signaling pathway that controls neurite outgrowth. EIF6 phosphorylation promotes its nuclear export. Triggers down-regulation of dopamine receptors in the forebrain. Activates DCK in vitro by phosphorylation. TOP2A phosphorylation favors DNA cleavable complex formation. May regulate the formation of the mitotic spindle apparatus in extravillous trophoblast. Modulates connexin-43/GJA1 gap junction assembly by phosphorylation. Probably involved in lymphocyte physiology. Regulates fast synaptic transmission mediated by glutamate.<ref>PMID:10606744</ref> <ref>PMID:12270943</ref> <ref>PMID:14761950</ref> <ref>PMID:16027726</ref> <ref>PMID:17962809</ref> <ref>PMID:17562708</ref> <ref>PMID:19043076</ref> <ref>PMID:19339517</ref> <ref>PMID:20637175</ref> <ref>PMID:20041275</ref> <ref>PMID:20048001</ref> <ref>PMID:20699359</ref> <ref>PMID:20696890</ref> <ref>PMID:20407760</ref> <ref>PMID:21084295</ref> <ref>PMID:21422228</ref>
		+	== References ==
		+	<references/>
		+	__TOC__
		+	</StructureSection>
		+	[[Category: Alscher, V.]]
		+	[[Category: Berg, S.]]
		+	[[Category: Bischof, J.]]
		+	[[Category: Garcia-Reyes, B.]]
		+	[[Category: Knippschild, U.]]
		+	[[Category: Kohlhof, H.]]
		+	[[Category: Leban, J.]]
		+	[[Category: Othersen, O.]]
		+	[[Category: Pospiech, I.]]
		+	[[Category: Richter, J.]]
		+	[[Category: Vitt, D.]]
		+	[[Category: Zaja, M.]]
		+	[[Category: Ck1delta]]
		+	[[Category: Ck1epsilon]]
		+	[[Category: Phosphorylation]]
		+	[[Category: Small molecule inhibitor]]
		+	[[Category: Transferase]]

OCA: Protected "4tw9" [edit=sysop:move=sysop]

2014-07-09T06:59:54Z

Protected "4tw9" [edit=sysop:move=sysop]

←Older revision

Revision as of 06:59, 9 July 2014

OCA: New page: '''Unreleased structure''' The entry 4tw9 is ON HOLD Authors: Richter, J., Bischof, J., Zaja, M., Kohlhof, H., Othersen, O., Vitt, D., Alscher, V., Pospiech, I., Garcia-Reyes, B., Berg,...

2014-07-09T06:59:53Z

New page: '''Unreleased structure''' The entry 4tw9 is ON HOLD Authors: Richter, J., Bischof, J., Zaja, M., Kohlhof, H., Othersen, O., Vitt, D., Alscher, V., Pospiech, I., Garcia-Reyes, B., Berg,...

New page

'''Unreleased structure'''

The entry 4tw9 is ON HOLD

Authors: Richter, J., Bischof, J., Zaja, M., Kohlhof, H., Othersen, O., Vitt, D., Alscher, V., Pospiech, I., Garcia-Reyes, B., Berg, S., Leban, J., Knippschild, U.

Description: Difluoro-dioxolo-benzoimidazol-benzamides as potent inhibitors of CK1delta and epsilon with nanomolar inhibitory activity on cancer cell proliferation